Redefining Care.
Advancing COPD and Other Respiratory Therapies.
Expedition Therapeutics is developing novel treatments for inflammatory and respiratory diseases with the potential to fundamentally transform patient care worldwide.
ABOUT US
At Expedition Therapeutics, we believe that disease-controlling treatments that address fundamental disease mechanisms should be the new standard for chronic obstructive pulmonary disease (COPD). Our therapy is designed to target neutrophilic inflammation, a novel and clinically validated pathway that is a major driver of tissue damage, airway remodeling, and progressive decline in lung function.
Our lead candidate, EXPD-101, is a potent, oral, once-daily DPP1 inhibitor being developed for COPD, with the potential to deliver continuing improvement for millions of patients who currently have no disease-controlling treatment options.
SCIENCE
EXPD-101: A Next-Generation DPP1 Inhibitor
Expedition is advancing EXPD-101, a next-generation oral DPP1 inhibitor engineered to selectively block activation of neutrophil serine proteases (NSPs), the enzymes that cause airway damage and disease progression. EXPD-101 directly targets neutrophilic inflammation, one of the major mechanisms driving COPD, without compromising neutrophil host surveillance or depleting neutrophil counts.
EXPD-101 is designed to deliver superb potency, safety, and pharmacokinetics, with the potential to be a first-in-class and best-in-class DPP1 therapy for COPD.
Novel Mechanism
Targets neutrophilic inflammation, addressing an unmet need for nearly 70% of COPD patients who lack effective treatment options.
Clinical Progress
Well-tolerated in Phase 1 with clear target engagement and once-daily oral dosing.
Global Development
Advancing into a global Phase 2 COPD trial, with additional indication expansion potential in bronchiectasis, neutrophilic asthma and other neutrophil-driven diseases.
Leadership
Expedition Therapeutics is led by a seasoned team of biotech executives, scientists, and clinicians with decades of success across drug discovery, clinical development, regulatory strategy, and commercialization. Together, we are united by a single mission: to accelerate the arrival of first-in-class, best-in-class disease-controlling therapies for COPD and other respiratory diseases.
Media
- Press Release
- October 9, 2025
Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DPP1 inhibitor for COPD
SAN FRANCISCO, CA – October 9, 2025 – Expedition Therapeutics, a biotech company developing therapies for novel inflammatory and respiratory diseases, today announced the closing of an oversubscribed and upsized $165 million Series A financing. The round was co-led by Sofinnova Investments and Novo Holdings, with additional investment from Forbion, Dawn Biopharma (a platform controlled […]
Investors
Expedition is backed by leading global life sciences investors, including:
